NCT06192004

Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD

An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 83 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution. Patients initiating treatment for non-small cell lung cancer (NSCLC) will be prospectively followed to characterize risk factors, signs, and symptoms leading to onset, diagnosis, and treatment of pneumonitis/ILD should it occur.

Detailed description

This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution. Data will be collected prospectively from study sites using eCRFs and remotely from patients using a digital health tool.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
OTHER	None (Observational Study)	Not applicable since Observational Study

Timeline

• Start date: 2024-01-05
• Primary completion: 2025-04-30
• Completion: 2025-04-30
• First posted: 2024-01-05
• Last updated: 2025-06-03

Locations

23 sites across 1 country: United States